Zhejiang Medicine to Market Antibiotic in the US After Getting FDA Nod; Shares Jump 3% - Marketscreener.com

1 year ago 40

Homepage Equities China Shanghai Stock Exchange Zhejiang Medicine Co., Ltd. News Summary     600216   CNE0000010J2 (600216) Add to my list   Report End-of-day punctuation Shanghai Stock Exchange  -  2023-01-19 11.71 CNY   +0.52% 12:39a Zhejiang Medicine to Market Antibiotic successful the US After Getting FDA Nod; Shares Jump 3% MT 2022 Zhejiang Medicine Co., Ltd.(SHSE:600216) dropped from Shanghai Stock Exchange Health Care Sector Index CI 2022 Zhejiang Medicine Unit Gets Clinical Trial Approval For Anti-Biliary Tract Cancer Drug MT Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds   Summary Most relevant All News Other languages Press Releases Official Publications Sector news 01/30/2023 | 12:39am EST MT Newswires 2023 All quality about ZHEJIANG MEDICINE CO., LTD. 12:39a Zhejiang Medicine to Market Antibiotic successful the US After Getting FDA Nod; Shares Jump 3% MT 2022 Zhejiang Medicine Co., Ltd.(SHSE:600216) dropped from S.. CI 2022 Zhejiang Medicine Unit Gets Clinical Trial Approval For Anti-Biliary Tract Cancer Drug MT 2022 Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended Septembe.. CI 2022 Brokerage CLSA vice-chairman Charles Lin resigns RE 2022 Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2.. CI 2022 Zhejiang Medicine Co., Ltd.(SHSE:600216) added to Shang.. CI 2022 Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March .. CI 2022 TaiGen Biopharmaceuticals Turns to Profit successful 2021 MT 2021 Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended Septembe.. CI Financials Sales 2022 7 973 M 1 175 M 1 175 M Net income 2022 677 M 99,8 M 99,8 M Net Debt 2022 - - - P/E ratio 2022 16,7x Yield 2022 1,79% Capitalization 11 222 M 1 654 M 1 654 M Capi. / Sales 2022 1,41x Capi. / Sales 2023 1,32x Nbr of Employees 5 901 Free-Float 57,8% Chart ZHEJIANG MEDICINE CO., LTD. Duration : Period : Technical investigation trends ZHEJIANG MEDICINE CO., LTD. Short Term Mid-Term Long Term Trends Bearish Bearish Bearish Income Statement Evolution Consensus Sell Buy Mean consensus BUY Number of Analysts 1 Last Close Price 11,71 CNY Average people price 16,03 CNY Spread / Average Target 36,9% EPS Revisions Managers and Directors Chun Lei Lu President, General Manager & Director Chun Bo Li Chairman Bao Quan Zhu Independent Director Dong Liang Huang Independent Director Jian Wei Zhu Independent Director Sector and Competitors 1st jan. Capi. (M$) ZHEJIANG MEDICINE CO., LTD. 0.17% 1 654 JOHNSON & JOHNSON -4.77% 439 835 ELI LILLY AND COMPANY -6.49% 325 056 NOVO NORDISK A/S 1.06% 312 363 ROCHE HOLDING AG -0.40% 277 685 MERCK & CO., INC. -5.02% 267 180

1. Homepage
2. Health
3. Zhejiang Medicine to Market Antibiotic in the US After Getting FDA Nod; Shares Jump 3% - Marketscreener.com